Affinity isolation of protein serine/threonine phosphatases on the immobilized phosphatase inhibitor microcystin-LR identified histone deacetylase 1(HDAC1), HDAC6, and HDAC10 as novel components of cellular phosphatase complexes. Other HDACs, specifically HDAC2, -3, -4, and -5, were excluded from such complexes. In vitro biochemical studies showed that recombinant HDAC6, but not HDAC4, bound directly to the protein phosphatase (PP)1 catalytic subunit. No association was observed between HDAC6 and PP2A, another major protein phosphatase. PP1 binding was mapped to the second catalytic domain and adjacent C-terminal sequences in HDAC6, and treatment of cells with trichostatin A (TSA) disrupted endogenous HDAC6⅐PP1 complexes. Consistent with the inhibition of tubulin deactylase activity of HDAC6, TSA enhanced cellular tubulin acetylation, and acetylated tubulin was present in the PP1 complexes from TSA-treated cells. Trapoxin B, a weak HDAC6 inhibitor, and calyculin A, a cell-permeable phosphatase inhibitor, had no effect on the stability of the HDAC6⅐PP1 complexes or on tubulin acetylation. Mutations that inactivated HDAC6 prevented its incorporation into cellular PP1 complexes and suggested that when bound together both enzymes were active. Interestingly, TSA disrupted all the cellular HDAC⅐phosphatase complexes analyzed. This study provided new insight into the mechanism by which HDAC inhibitors elicited coordinate changes in cellular protein phosphorylation and acetylation and suggested that changes in these protein modifications at multiple subcellular sites may contribute to the known ability of HDAC inhibitors to suppress cell growth and transformation.
Reversible protein phosphorylation is the most prevalent protein modification regulating eukaryotic cell physiology. Identification of numerous acetyltransferases and deacetylases suggests that protein acetylation also controls many physiological events (1) . Studies of histone acetylation and phosphorylation show that both protein modifications play key roles in chromatin remodeling and gene transcription (2) . The cellular mechanisms that coordinate the acetylation and phosphorylation of histones and other cellular proteins are still poorly understood.
The precise orchestration of protein phosphorylation and acetylation is best exemplified during growth factor-stimulated phosphorylation and acetylation of histone H3 (3) . Histone H3 is phosphorylated on serine 10 in fibroblasts in response to mitogens or following oncogenic transformation (4) . Several kinases (5) (6) (7) (8) catalyze the phosphorylation of histone H3 at serine 10 to generate an improved substrate for acetyltransferases that modify the adjacent lysine 14 (9) . Conversely, serine 10 phosphorylation inhibits the acetylation of histone H3 at lysine 4 (10) . The changes in phosphorylation and acetylation of histone H3 create novel platforms that recruit nuclear factors and/or stabilize pre-existing nuclear complexes required for chromatin remodeling and gene expression (2) . How cells orchestrate the ordered phosphorylation and acetylation of histone H3 or their subsequent reversal remains unknown.
Formation of multiprotein complexes can coordinate the activities of various enzymes incorporated into these complexes to control cell function. For example, the assembly and disassembly of complexes containing acetyltransferases and deacetylases may coordinate these two opposing activities to control the genetic program required for cell differentiation (11) . Similarly, cell cycle-dependent association of the Ipl1/ Aurora kinases and protein phosphatase 1 (PP1) 1 coordinates their reciprocal phosphorylation-dephosphorylation (12) and, in turn, regulates histone H3 phosphorylation during mitosis in yeast, worms, and mammalian cells (13, 14) . However, few mechanisms that coordinate protein acetylation with phosphorylation have been identified. Recent studies suggest that growth factors promote the association of the protein kinase Rsk-2 with CREB-binding protein, a histone acetyltransferase (15) and may coordinate the phosphorylation of the nuclear factor CREB with the acetylation of histones to activate gene transcription. Recent studies also identified a CREB-associated complex that contained PP1, several other phosphatases, and the two Class I HDACs, HDAC1 and HDAC2 (16) . How this complex was assembled or how it contributed to the expression of the numerous CREB-activated genes was not established. Recent studies suggest that deacetylase activity can have both positive and negative effects on cAMP activation of CREB target genes (17) and this may in part be mediated by the cAMP-mediated phosphorylation and acetylation of CREB (18) as well as other proteins required for gene activation.
HDACs exist in both nuclear and cytoplasmic compartments. The present studies were directed at identifying cellular complexes formed by HDACs in multiple subcellular compartments and at establishing the interplay between HDACs and phosphatases that potentially regulated the covalent modification of cellular proteins. These studies established that some but not all HDACs formed complexes containing protein serine/threonine phosphatases. Further biochemical studies focused on the cytosolic complex formed by HDAC6 and PP1, both enzymes shown to regulate microtubule functions (19, 20) . Our studies demonstrated that HDAC6 directly bound PP1 and showed that inactivation of HDAC6 by either pharmacological inhibitors or mutagenesis disrupted the cellular HDAC6⅐PP1 complex. Inhibition of HDAC6 increased tubulin acetylation in cells, and acetylated tubulin was associated with the PP1 complexes. These data suggested that the HDAC6⅐PP1 complex controlled microtubule dynamics. We made the remarkable observation that the broad specificity deacetylase inhibitor, trichostatin A, disrupted several HDAC⅐phosphatase complexes, suggesting a novel mechanism for coordinating protein phosphorylation and acetylation in mammalian cells. Because the increased histone acetylation elicited by TSA and other broad-acting deacetylase inhibitors is by itself insufficient to inhibit cell growth (21) and transformation (22) , our data suggested that the disruption of HDAC⅐phosphatase complexes and the ensuing changes in protein acetylation and phosphorylation may together account for the anticancer activity of these compounds.
MATERIALS AND METHODS
Reagents-LipofectAMINE™ was obtained from Invitrogen; anti-FLAG® M2 affinity gel, phosphorylase kinase, trichostatin A (TSA), and dithiothreitol from Sigma; CNBr-activated Sepharose™ from Amersham Biosciences; phosphorylase b from Calzyme; microcystin-LR and calyculin A from Alexis; Ni ϩ -NTA-agarose from Qiagen; Escherichia coli BL21(DE3)pLysS cells and QuikChange site-directed mutagenesis kit from Stratagene; digoxigenin labeling kit from Roche Applied Science; and [␥-32 P]ATP (3000 Ci/mmol) from PerkinElmer Life Sciences. PP1 catalytic subunit was purified from rabbit skeletal muscle as described by DeGuzman and Lee (23) . The following antibodies (at dilutions shown in brackets) were used in this study: anti-FLAG M2 (1:1000), anti-tubulin (1:1000), and anti-acetylated tubulin (1:1000) monoclonal antibodies from Sigma; anti-PP1 monoclonal antibody (1: 1000) from BD Transduction Labs; anti-HDAC6 (1:250) and sheep anti-rabbit horseradish peroxidase-linked IgG (1:3000) from Amersham Biosciences. Purified bovine heart PP2A catalytic subunit was provided by Brian Wadzinski (Vanderbilt University).
Plasmids encoding FLAG-tagged human HDAC4, -5, and -6 as well as an inactive HDAC6 (H216A/H611A) were provided by S. L. Schreiber of Harvard University (24) . Plasmids expressing WT and catalytically inactive HDAC10 were generated as previously described (25) . HDAC6 ⌬RV was generated by digesting HDAC6 cDNA with EcoRV and SpeI and ligating the flanking DNA fragments. C-terminal deletions of HDAC6, specifically 1-789, 1-503, and 1-410 were generated by PCR with a C-terminal FLAG tag incorporated into the 3Ј primers. The PCR fragments were inserted into the HindIII and EcoRV sites in pcDNA3. Baculovirus expression (Invitrogen) was used to express hexahistidinetagged HDAC4 and -6. All cDNAs were verified by DNA sequencing by Duke Comprehensive Cancer Center Facility.
Expression of HDACs in Cultured Cells-HEK293T cells were grown in Dulbecco's modified Eagle medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS) and penicillin-streptomycin-amphotericin B (Invitrogen) at 37°C in an atmosphere of 5% CO 2 /95% air. DNA transfections were performed in 6-well plates using 6 l of LipofectAMINE™ and 2 g of plasmid DNA in serum-free DMEM. After 5 h, cells were transferred to fresh DMEM containing 10% (v/v) FBS.
Isolation of Cellular Phosphatase Complexes-HEK293T cells grown to 80 -90% confluence were treated with either 5 M TSA, 100 nM trapoxin B (TpxB), or 100 nM calyculin A. Control cells were treated with vehicle, 0.1% (v/v) dimethyl sulfoxide. Cells washed in phosphate-buffered saline were lysed in NETN buffer (10 mM Tris-HCl, pH 7.5 containing 100 mM NaCl, 0.5% (v/v) Nonidet P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 2 g/ml leupeptin, 1 g/ml aprotonin, and 1 g/ml pepstatin A). Cellular PP1 complexes were isolated by chromatography of the lysates on microcystin-LR-Sepharose (26) . Bound proteins were eluted in 50 l of SDS sample buffer and subjected to SDS-PAGE and immunoblotting with appropriate antibodies.
The HDAC6⅐PP1 complexes were also analyzed by co-immunoprecipitation. HEK293T lysates containing FLAG-HDAC proteins were incubated with 25 l of anti-FLAG M2 beads for 2 h at 4°C, and the beads were washed with phosphate-buffered saline, eluted with SDS sample buffer, and analyzed by immunoblotting.
Phosphorylase Phosphatase Assays-Hexahistidine (His)-tagged HDAC proteins were purified on Ni ϩ -NTA-agarose. Purified PP1 or PP2A (0.02 unit) was incubated with increasing concentrations of His-HDAC6 or His-HDAC4 for 15 min at 37°C and Ni ϩ -NTA-agarose for 30 min. Bound proteins were removed by centrifugation and the supernatant analyzed for phosphorylase phosphatase activity (27) .
PP1 Far-Westerns-PP1 binding to recombinant HDAC6 was analyzed by Far-Western using recombinant human PP1␣ conjugated to digoxigenin (28) . The bound PP1 was detected by immunoblotting with an anti-digoxigenin antibody and visualized by an alkaline phosphatase reaction (Amersham Biosciences).
RESULTS

Cellular Protein Phosphatase Complexes Containing
HDACs-Earlier studies used Far-Westerns with recombinant PP1␥1 to identify two cDNAs that encoded a "histone deacetylase-like protein" (GenBank TM accession number AJ011972) from a HeLa cDNA library (29) . Recent studies also suggested that HDAC1 (16) and -2 (30) existed in nuclear complexes that also contained PP1 and other phosphatases. How these complexes were assembled and their functional roles in cells remain unknown. To extend and validate these observations, we expressed HDAC1, -2, -3 (Class I HDACs) and HDAC4, -5, -6, and -10 (Class II HDACs) as FLAG-tagged proteins in HEK293T cells (Fig. 1A) . Immunoblotting with an anti-FLAG antibody showed that all fusion proteins were effectively expressed (Fig. 1B, bottom) . To isolate the cellular phosphatase complexes, cell lysates were subjected to affinity chromatography on MC (microcystin-LR)-Sepharose (26). Immunoblotting with a pan anti-PP1 antibody established that MC-Sepharose bound equivalent amounts of this major serine/threonine phos-
FIG. 1. Cellular protein phosphatase complexes contain histone deacetylases.
A, schematic representation of Class I and Class II HDAC family members, with light gray boxes representing their conserved catalytic domains. The C-terminal HDAC domain in HDAC10 is partial and lacks catalytic activity. B, phosphatase complexes were affinity purified from HEK293T cells using MC-Sepharose; the bound proteins were subjected to SDS-PAGE and immunoblotting (IB) with anti-FLAG and anti-PP1 antibodies. Lysates were also immunoblotted with anti-FLAG antibody to establish equivalent expression of all HDACs. Molecular mass markers (kDa) are indicated.
phatase from all extracts (Fig. 1B) . Immunoblotting with anti-FLAG antibody showed that HDAC6, HDAC1, and HDAC10 were present in the MC-bound phosphatase complexes. HDAC2, HDAC3, HDAC4, and HDAC5 were either excluded from phosphatase complexes or were components of inactive phosphatase complexes that did not bind MC, which associates with the phosphatase catalytic center (31) .
HDAC6 Directly Binds the PP1 Catalytic Subunit-To investigate the direct association of PP1 with HDACs, we undertook Far-Westerns of purified hexahistidine-tagged HDAC6 and -4 proteins using digoxigenin-conjugated PP1␣ (28) . Immunoblotting with anti-digoxigenin antibody showed PP1 bound HDAC6 (0.3-2.1 g of total protein) in a concentration-dependent manner ( Fig. 2A) . At similar concentrations, HDAC4 failed to bind PP1. The data suggested that PP1 displayed at least 10-fold greater preference for binding to HDAC6 over HDAC4.
PP1 and PP2A comprise more than 90% of serine/threonine phosphatase activity in mammalian cells and bind MC with equal affinity. To examine specificity of HDAC6 for these phosphatases, we incubated rabbit skeletal muscle PP1 and bovine heart PP2A with increasing concentrations of recombinant His-HDAC6 or -4. HDAC⅐phosphatase complexes were sedimented using Niϩ-NTA agarose, and residual phosphatase activity was assayed using the standard substrate, phosphorylase a. Consistent with the Far-Westerns, His-HDAC6 depleted PP1 activity in a dose-dependent manner. 0.3 g of His-HDAC6 (Fig. 2B , filled triangles) depleted more than 50% of PP1 activity. PP1 did not bind Niϩ-NTA agarose in the absence of His-HDAC6 (data not shown). The specificity of the HDAC6-PP1 interaction was established by the finding that at comparable concentrations His-HDAC6 did not sediment or deplete PP2A activity (Fig. 2B, filled diamonds) . Under identical assay conditions, His-HDAC4 failed to sediment both PP1 (Fig. 2B , open circles) and PP2A (data not shown). In experiments that utilized 50 -100-fold higher concentrations of PP1, immunoblotting of pellets and supernatants demonstrated that the PP1 removed from solution by His-HDAC6 bound to Niϩ-NTA agarose could be fully accounted for in the pellet (data not shown).
Conversely, His-HDAC6 did not bind MC-Sepharose unless preincubated with PP1. Preincubation of HDAC6 with PP2A, which bound MC-Sepharose, did not recruit His-HDAC6 to the affinity matrix (data not shown). This established that HDAC6 selectively bound PP1, and an HDAC6⅐PP1 complex could be assembled in the absence of other proteins.
PP1 Binds C-terminal Domain of HDAC6 -To define the PP1-binding domain in HDAC6, we expressed FLAG-HDAC6 proteins with serial C-terminal deletions (Fig. 3A) in HEK293T cells and examined their incorporation into endogenous PP1 complexes. Immunoblotting lysates with anti-FLAG antibody established equivalent expression of HDAC6 polypeptides (Fig.  3B) . Immunoblotting with an anti-PP1 antibody showed that MC-Sepharose sedimented PP1 from all lysates (Fig. 3B) . Immunoblotting MC-bound proteins with an anti-FLAG antibody established that only WT-HDAC6 (1-1215) and HDAC6 (⌬BUZ, Binder of Ubiquitin Zinc Finger) bound PP1. HDAC6 (1-781), (1-503), and (1-410) failed to bind PP1 (Fig. 3B) . This suggested that the region between amino acids 781 and 931 in HDAC6 was required for PP1 binding.
We also undertook pull-downs from untransfected HEK293T cell lysates using GST⅐HDAC6 (1-556), (556 -832), and (832-1215) (32) and immunoblotted the proteins bound to glutathione-Sepharose with an anti-PP1 antibody. These data showed that GST⅐HDAC6 (832-1215) bound PP1. Weak PP1 binding was seen to GST⅐HDAC6 (556 -832). However, the N-terminal
FIG. 2. HDAC6 binds PP1 in vitro.
A, Far-Westerns of purified recombinant His-HDAC6 and -4 that were subjected to 10% SDS-PAGE gel, transferred to polyvinylidene difluoride membrane, and overlaid with digoxigenin-conjugated PP1␣. Molecular mass markers (kDa) are indicated. B, rabbit skeletal muscle PP1 was incubated with increasing amounts of His-HDAC6 (triangles) or His-HDAC4 (diamonds). The HDAC⅐PP1 complexes were sedimented using Ni-NTA agarose, and supernatants were assayed for phosphorylase phosphatase activity (see "Materials and Methods"). Bovine heart PP2A was also incubated with His-HDAC6 (circles) and supernatants assayed as described above. domain GST⅐HDAC6 (1-556) failed to bind PP1. 2 Together, the data hinted at an extended PP1-binding site located between amino acids 556 and 931. Further studies are needed to define the precise mechanism for PP1 binding to not only HDAC6 but also HDAC1 and -10, which were also incorporated into cellular PP1 complexes.
Active HDAC Binds PP1-The PP1-binding domain in HDAC6 (556 -931) encompassed the second HDAC catalytic domain. To examine the importance of HDAC activity in PP1 binding, we isolated endogenous HDAC6⅐PP1 complexes from control HEK293T cells using MC-Sepharose (Fig. 4A) . Treatment of cells with the HDAC inhibitor TSA inhibited HDAC6 and increased the acetylation of tubulin, a physiological substrate of the enzyme detected by immunoblotting with an antiacetyl-tubulin antibody (33) . While TSA treatment had no effect on the amount of PP1 bound to MC-Sepharose, no HDAC6 was detected in these complexes. Brief exposure to TSA following cell homogenization (TSA*) also disrupted the HDAC6⅐PP1 complex, suggesting that this event did not require the increased acetylation of cellular proteins. In contrast, TpxB, a very weak HDAC6 inhibitor (34), had no effect on HDAC6 binding to endogenous PP1 or tubulin acetylation in HEK293T cells. This suggested that the HDAC inhibitors targeted HDAC6 to disrupt the cellular HDAC6⅐PP1 complex. Consistent with the ability of the HDAC6⅐PP1 complex to bind MC, the cell-permeable PP1 inhibitor calyculin A had no effect on the formation of a cellular HDAC6⅐PP1 complex.
We also expressed WT and a catalytically inactive mutant of FLAG-HDAC6 (H216A/H611A) in HEK293T cells (Fig. 4B) . As seen with endogenous HDAC6, FLAG-HDAC6 bound PP1 and was concentrated by MC-Sepharose. Treatment of cells with TSA or post-homogenization addition of TSA disrupted the FLAG-HDAC6⅐PP1 complex. In contrast, catalytically inactive FLAG-HDAC6, although expressed at similar levels, was not incorporated into cellular PP1 complexes. These data suggested that both HDAC6 and PP1 were active in the cellular HDAC6⅐PP1 complex. Similar results were obtained with HDAC10 (data not shown).
We also examined the effect of TSA on phosphatase complexes containing FLAG-tagged HDAC1, -6, and -10 expressed in HEK293T cells (Fig. 4C) . All three HDACs were expressed at near equivalent levels and incorporated into phosphatase complexes that bound MC-Sepharose. TSA treatment prevented the incorporation of all three HDACs into the MC-bound complexes. This suggested that the broad specificity HDAC inhibitor, TSA, disrupted multiple HDAC⅐phosphatase complexes.
As an additional control we analyzed the effect of TSA on PP1 binding to GADD34, which targets PP1 to regulate protein translation (35) . Expression of FLAG-GADD34 followed by affinity chromatography on MC-Sepharose showed that GADD34 C, FLAG-HDACs were expressed in HEK293T cells as described in Fig. 1 and phosphatase complexes isolated on MCS. Cell lysates and MCS-bound proteins were immunoblotted with anti-FLAG and anti-PP1 antibodies. D, HEK293T cells were transfected with plasmids expressing either FLAG-tagged WT-HDAC6 or FLAG-GADD34, a known PP1 regulator. MCS was used to isolate phosphatase complexes from cells treated with vehicle or TSA (as described in panels A and B). MCS-bound proteins were immunoblotted with anti-FLAG and anti-PP1 antibodies.
was incorporated into cellular PP1 complexes. TSA had no effect on the formation of a cellular PP1⅐GADD34 complex (Fig.  4D) . Similar results were obtained with the PP1 regulator, neurabin, which targets PP1 to the actin cytoskeleton (data not shown; Ref. 36) . This established that TSA and other broad-acting HDAC inhibitors selectively disrupted cellular HDAC⅐phosphatase complexes. (19, 33, 37) . To define the role of the HDAC6⅐PP1 complex, we immunoblotted MC-bound proteins with an anti-tubulin antibody. A small fraction (Ͻ1%) of the total cellular tubulin was present in the endogenous HDAC6⅐PP1 complex from untransfected HEK293T cells (data not shown). Immunoblotting with anti-acetyl-tubulin antibody showed a complete absence of acetylated tubulin in the HDAC6⅐PP1 complex isolated from control cells (Fig. 5) . HDAC6 inhibition by TSA had no effect on the amount of total tubulin bound to MC-Sepharose (data not shown) but increased the acetylated tubulin present in these PP1 complexes by 8 -10-fold (Fig. 5) . These data suggested that HDAC6⅐PP1 bound tubulin and maintained it in a deacetylated state. The disruption of the HDAC6⅐PP1 complex by TSA enhanced the acetylation of tubulin that remained bound to PP1. Alternatively, disruption of the HDAC6⅐PP1 complex may recruit PP1 to acetylated tubulin. DISCUSSION Emerging evidence suggests that protein phosphorylation and acetylation may share common targets to coordinate eukaryotic physiology. Thus, the cell-permeable phosphatase inhibitor, okadaic acid, enhanced both protein phosphorylation and acetylation (38) ; conversely, HDAC inhibitors elicited parallel changes in protein acetylation and phosphorylation (39) . Identification of cellular complexes containing protein phosphatases and HDACs suggested a potential new mechanism by which both enzymatic activities may be coordinated in the covalent modification of proteins that regulate cell growth and function.
HDAC6 Inhibition Enhances Acetylation of ␣-Tubulin Present in the Cellular PP1 Complex-HDAC6 catalyzes ␣-tubulin deacetylation in mammalian cells
Canettieri et al. (16) recently demonstrated that immunoprecipitation of the nuclear transcription factor CREB also sedimented several HDACs and phosphatases. Specifically, the anti-CREB immunoprecipitates contained HDAC1, HDAC2, PP1, PP2A, and PP4. Elevation of intracellular cAMP increased CREB phosphorylation and histone acetylation and activated CREB-regulated genes. The authors also showed that TSA, a broad-acting HDAC inhibitor, attenuated CREB dephosphorylation, but the mechanism by which TSA modified the activity of PP1, a known CREB phosphatase (40) , remained unknown. In this regard, the present studies confirmed the existence of a cellular HDAC1⅐PP1 complex and showed that this complex was disrupted by the treatment of cells with TSA. This predicted the release of PP1 from the nuclear CREB⅐ HDAC1 complex and accounted for the attenuated dephosphorylation of CREB (16) . Furthermore, our studies showed that not only HDAC1 but also HDAC6 and HDAC10 bound cellular phosphatases, whereas HDAC2, HDAC3, HDAC4, and HDAC5 were not incorporated into similar phosphatase complexes that bound microcystin-LR. Thus, the presence of HDAC2 in the nuclear CREB complex as reported by Canettieri et al. (16) most likely occurred by other mechanisms such as the known heterodimerization of HDAC1 and -2 or association of HDAC2 with other nuclear proteins (41) . The indirect recruitment of HDAC2 to a nuclear PP1 complex is also consistent with the recent identification of a multiprotein complex containing NIPP1, a known PP1-binding protein, and the polycomb group protein, EED, also identified as a NIPP1-binding protein. Because EED also bound HDAC2, this generated an HDAC⅐phosphatase complex that potentially repressed the transcription of EED-regulated genes (30) . Finally, the recruitment of other phosphatases, such as PP2A, to the DNA-bound CREB complex must also occur via proteins other than HDAC1 because no direct association of HDAC1 with PP2A could be demonstrated.
HDAC6 is unique among known HDACs in being predominantly cytoplasmic (33) , where it catalyzes ␣-tubulin deacetylation (37), destabilizes microtubules (19) , and enhances cell motility (33) . A recent report suggested that a small fraction of HDAC6 may shuttle into the nucleus under conditions of growth arrest and cell differentiation (42) to be incorporated into nuclear complexes that contained the nuclear matrix-associated protein, Runx2 (43) . Alternately, a cytosolic HDAC6 suppresses gene expression by its association with the transcription factor NFB (44) to prevent its entry into the nucleus to activate downstream genes. The present studies identify a novel association of HDAC6 with a major cellular phosphatase, namely PP1. Our studies established the association of HDAC6 with PP1 using a yeast two-hybrid assay (data not shown) and using purified proteins. These studies showed that HDAC6 bound PP1 in the absence of other cellular proteins and potentially recruited the HDAC6⅐PP1 complex to microtubules.
The HDAC6 catalytic domain binds ␣-and ␤-tubulin, two major components of cytoplasmic microtubules, and catalyzes the deacetylation of ␣-tubulin (37). We observed a small fraction of the total cellular ␣-tubulin in the HDAC6⅐PP1 complex in control cells. Most importantly, treatment with the broad specificity HDAC inhibitor TSA promoted the disassembly of the HDAC6⅐PP1 complex and greatly enhanced the acetylation of ␣-tubulin that was associated with the remaining PP1 complex. By comparison, trapoxin B, a very weak HDAC6 inhibitor, did not disrupt the HDAC6⅐PP1 complex and also failed to promote tubulin acetylation. Because ␣-tubulin acetylation increases following microtubule assembly, our data may suggest that PP1 facilitates the recruitment of HDAC6 to modulate microtubule dynamics. In this regard, the prevailing evidence implicates HDAC6 in destabilizing microtubules (19) . By contrast, PP1, which is also recruited to microtubules by the microtubule-associated protein (MAP) Tau, dephosphorylates Tau and other MAPs to stabilize microtubules (20) . Thus, in contrast to the nuclear HDAC1⅐PP1 complex that brings together two enzymes, which may both repress gene transcrip- tion, the cytoplasmic HDAC6⅐PP1 complex may function antagonistically to regulate microtubule dynamics.
Using C-terminal deletions, we mapped PP1 binding to the second HDAC domain and adjacent C-terminal sequences. Because HDAC6 activity was essential for PP1 binding, C-terminal deletions that decreased or even abolished HDAC6 activity (data not shown) may not define the PP1-binding domain. To circumvent this, we also demonstrated the direct PP1 binding to GST⅐HDAC6 proteins encompassing the C terminus (32) . These studies suggested that PP1 bound to an extended region of HDAC6, comprising as much as 400 amino acids. Close examination of this region of HDAC6 indicated the absence of a canonical PP1-binding motif, K(V)-I(R)-X-F, that is conserved in many known PP1 regulators (45) . This suggested a novel mode of PP1 binding to HDAC6. Recent studies suggested that tubulin deacetylase activity of HDAC6 was localized to the second HDAC domain because selective inhibition of this domain abrogated the deacetylation of tubulin but had a minor effect of histone deacetylation, presumably catalyzed by the N-terminal HDAC domain (46) . Thus, TSA most likely binds to the C-terminal or second HDAC6 catalytic domain to elicit the conformational change that disrupts PP1 association. Among the known HDACs, HDAC6 most closely resembles HDAC10, which also binds PP1. Because HDAC10 contains a partial second HDAC domain and lacks critical sequences required for deacetylase activity, TSA must bind the N-terminal HDAC domain to disrupt the HDAC10⅐PP1 association. This may also occur with HDAC1, which contains a single HDAC domain. However, the mutation (H141A) that inactivates HDAC1 had little impact on the ability of HDAC1 to recruit PP1 to the nuclear CREB complex (16) . In contrast to HDAC1, the analogous mutations in HDAC6 (H216A/H611A) and HDAC10 (H135A) were observed in this study to disrupt PP1 binding. This suggested some differences in association of PP1 with these three HDACs. In contrast, pharmacological inhibition by TSA disrupted all cellular PP1 complexes containing HDAC1, -6, and -10. Clearly, more work is required to define the mode of PP1 binding to HDACs and establish the role of the PP1⅐HDAC complexes in cell function. The cell-permeable phosphatase inhibitors, okadaic acid and calyculin A, had no effect on cellular PP1⅐HDAC complexes and most likely target a different mechanism to elicit parallel changes in protein phosphorylation and acetylation (39) .
HDAC1 and -2, like many other HDACs, are phosphoproteins and are dephosphorylated by PP1 (38) . HDAC6 is also phosphorylated in cells 3 and might similarly be dephosphorylated by PP1. By analogy to other HDACs, the phosphorylation of HDAC6 may regulate either its enzyme activity or its association (38, 47) with other proteins as seen for HDAC11 (48) or control its cytoplasmic-nuclear shuttling as noted for HDAC7 (49) and -4 (50). HDAC6 phosphorylation could also modulate the function of the C-terminal BUZ or PAZ domain that bind ubiquitin-conjugated proteins (51) and deubiquinating enzymes and thereby regulate the ubiquitination and turnover of HDAC6 (32) . In conclusion, more work is required to define the physiological roles of cellular HDAC⅐phosphatase complexes, but our studies suggest that the anti-neoplastic activity of HDAC inhibitors (52) may in part be associated with the disassembly of HDAC⅐phosphatase complexes and resulting changes in protein acetylation and phosphorylation may inhibit cell growth and transformation.
